With cybercrime on the rise, data security is both a growing business and a financial risk for companies today. In this issue of Principles and Performance®, we discuss how effective corporate leadership can both minimize the threat and limit the damage for companies.
Parnassus evaluates the pricing structure of any pharmaceutical company under consideration for our portfolios. In this issue of Principles and Performance®, we focus on manufacturers’ drug pricing models, while recognizing that this is only one of many issues affecting the affordability and quality of medicine.
One important aspect of Parnassus’s ongoing ESG research and monitoring is encouraging positive change in portfolio companies through shareholder engagement. Read more in this month’s Principles and Performance®.
In the face of potential rollbacks on ESG issues with the incoming administration, Parnassus Investments remains
committed to delivering both Principles and Performance®.
In this month’s issue, Parnassus Investments has collected resources you can use to learn more about the environmental, social and governance topics we’ve touched on in Principles and Performance® during 2016.